Best Peptides for Growth Hormone Optimization: The Evidence Ranked

Tesamorelin is a synthetic, DPP-4-stabilized analog of full-length human GHRH given as a once-daily subcutaneous injection, and it is the single GH secretagogue to clear the RCT-plus-approval bar. In the pivotal six-month Phase III trial (n approximately 410 HIV patients with abdominal fat accumulation), 2 mg/day produced a highly significant rise in IGF-1 versus placebo, and dose-ranging work confirmed a dose-dependent effect. Across the Phase III program it reduced visceral adipose tissue by roughly 15-20 percent over 6-12 months without stripping beneficial subcutaneous fat, and in a separate randomized trial it reduced hepatic fat and slowed fibrosis in HIV-associated NAFLD. The critical honesty caveat: it is approved only for HIV-associated lipodystrophy, so every 'optimization' use is off-label, and the same label documents new-onset glucose intolerance, fluid retention with carpal tunnel, and IGF-1 elevation of unknown long-term consequence — 23 percent of users exceeded an IGF-1 standard-deviation score of +3 at 52 weeks. It ranks first not because it is safe for optimization but because it is the only peptide whose GH/IGF-1 and body-composition effects are demonstrated in multiple double-blind RCTs.

Best for

The reader who wants the single GH secretagogue with genuine randomized-trial and regulatory backing for raising GH/IGF-1 and reducing visceral fat.

Pricing

Rx only; brand EGRIFTA

Source: Falutz et al., NEJM 2007 (tesamorelin Phase III RCT)

MK-677 (ibutamoren) is an orally active, long-acting non-peptide ghrelin-receptor (GHS-R1a) agonist and the most rigorously studied oral GH secretagogue, though it is not FDA-approved for any indication. Its biomarker evidence rivals tesamorelin's: in a landmark two-year, double-blind, placebo-controlled RCT in healthy adults aged 60-81, 25 mg/day raised 24-hour mean GH roughly 1.8-fold and IGF-1 about 1.5-fold, restoring IGF-1 into the young-adult range in roughly half of treated subjects and sustaining it across the full two years. Fat-free mass rose by about 1.1 kg versus a loss on placebo. The decisive nuance is what did not happen: that same trial showed no significant improvement in muscle strength, physical function, or quality of life, and much of the fat-free-mass gain reflects water and body-cell mass rather than performance. A separate Alzheimer's trial found no disease benefit despite rising IGF-1 — a clean illustration that higher IGF-1 is not clinical benefit. It also carries the class's most consistent metabolic penalty, measurably raising fasting glucose and HbA1c and reducing insulin sensitivity. It ranks second because its biomarker case is as strong as tesamorelin's, but its own pivotal trial showed the elevated hormones did not translate into strength or function.

Best for

Someone weighing an oral option who understands the two-year RCT proved the biomarker rise but not a functional payoff — and accepts the glucose downside.

Pricing

Varies; unapproved / gray-market

Source: Nass et al., Ann Intern Med 2008 (2-year MK-677 RCT)

CJC-1295 is a synthetic GHRH(1-29) analog with stabilizing amino-acid substitutions that exists in two pharmacologically distinct forms routinely conflated in marketing. The 'with DAC' version uses a Drug Affinity Complex to covalently bind the peptide to serum albumin, extending its half-life to 5.8-8.1 days and giving tonic GH/IGF-1 elevation. Its one published human study — two randomized, double-blind, placebo-controlled ascending-dose trials over 28 and 49 days in healthy adults — showed CJC-1295 (DAC) raised plasma GH 2- to 10-fold for at least six days and IGF-1 1.5- to 3-fold for 9-11 days, with IGF-1 staying above baseline up to 28 days, well tolerated at 30-60 micrograms per kilogram. That is solid pharmacology but a single PK/PD study with no body-composition, strength, or long-term outcome data, hence Grade B. The catch that sinks its practical ranking: the 'no-DAC' version ('mod GRF 1-29') that people actually stack with ipamorelin has a half-life of roughly 30 minutes and no published human RCT of its own — its use is pure extrapolation, Grade D. Real human data exist, but only for the form almost nobody uses, and only as short pharmacology.

Best for

Understanding why 'CJC-1295 is clinically studied' is only half true — the studied DAC form is not the no-DAC form sold in stacks.

Pricing

Varies; unapproved / gray-market

Source: Teichman et al., JCEM 2006 (CJC-1295 DAC human PK/PD RCT)

Sermorelin is the 1-29 amino-acid fragment of GHRH — the shortest fragment retaining nearly full biological activity — and a short-acting GHRH-receptor agonist. Uniquely among the non-tesamorelin peptides here, it was once a genuine FDA-approved drug: brand Geref, approved in the early 1990s as a diagnostic for GH secretion and in 1997 for pediatric GH deficiency, then voluntarily discontinued in 2008 for commercial rather than safety reasons. It reliably stimulates pituitary GH in subjects with an intact pituitary — the basis of its diagnostic use — and daily subcutaneous sermorelin produced meaningful height-velocity gains in GHRH-responsive children, smaller than rHGH but with a milder side-effect profile. That regulatory pedigree and genuine human GH-stimulation data are why it outranks the mechanistic-only peptides. The honest weakness is the modern use case: adult 'optimization' data are thin and mostly pre-2008, with small or open-label studies reporting improved IGF-1, body composition and sleep in GH-deficient adults but no adequately powered contemporary RCT in healthy adults. Today it is available only as a compounded preparation whose standing is caught up in the same ongoing FDA peptide review. It is legitimate but under-evidenced for the purpose people now buy it.

Best for

Readers who value a peptide with a real FDA history and genuine GH-stimulation data over unproven newer stacks — while accepting the modern evidence is dated.

Pricing

Varies by compounding pharmacy

Source: FDA Geref / GHRH-analog NDA medical review, 2010

Ipamorelin is a selective synthetic pentapeptide ghrelin-receptor (GHS-R1a) agonist, widely regarded as the 'cleanest' GH-releasing peptide because it releases GH with a short (~2-hour) half-life without the cortisol, prolactin or aldosterone spikes seen with older GHRPs. It is the most-paired partner for CJC-1295 in 'stack' protocols and, in practice, the most popular optimization peptide of all. The evidence, however, is thin and indirect. Its one substantial human trial was a multicenter, double-blind, placebo-controlled Phase 2 study of intravenous ipamorelin for postoperative ileus after bowel resection — and it missed both primary and secondary efficacy endpoints (time to first tolerated meal 25.3 vs 32.6 hours placebo, P=0.15), establishing human tolerability but not efficacy. Critically, there is no human trial of ipamorelin for GH/IGF-1 optimization, body composition, anti-aging or athletic performance, and no human trial at all of the popular 'CJC-1295 plus ipamorelin' stack for any outcome; the synergy argument is mechanistic acute-release pharmacology, not outcome data. It also carries a meaningful negative regulatory signal: at the October 2024 PCAC meeting the FDA recommended ipamorelin not be included in the 503A bulks regulation. It ranks last because its real-world popularity is inversely proportional to its optimization evidence.

Best for

Understanding why the most-used 'optimization' peptide is also the least-proven — its case for the purpose is entirely mechanistic and anecdotal.

Pricing

Varies; unapproved / gray-market

Source: Beck et al., Int J Colorectal Dis 2014 (ipamorelin Phase 2 RCT, negative)